Effect of in vivo macrophage colony-stimulating factor on fungistasis of bronchoalveolar and peritoneal macrophages against Cryptococcus neoformans.
Macrophage colony-stimulating factor (M-CSF) given subcutaneously at a dose of 2.5 mg/kg of body weight (4.75 x 10(6) U/kg) to CD-1 male mice 8 to 12 weeks old was found to enhance significantly the fungistasis of bronchoalveolar macrophages (BAM) against Cryptococcus neoformans. When M-CSF was given 1, 3, 7, 9, or 13 days before an ex vivo challenge with C. neoformans, fungistasis was increased (P ranged from < 0.05 to < 0.001) compared with that induced by control BAM. A maximum effect was seen by days 1 and 3 after administration of M-CSF. Twenty-one days after M-CSF, BAM did not produce significantly enhanced fungistasis. M-CSF also significantly enhances the fungistatic effect of peritoneal macrophages (PM) if given 1, 3, and 7 days prior to testing against C. neoformans in comparison with control PM (P ranged from < 0.05 to < 0.001). PM did not produce enhanced fungistasis 9 or 13 days after administration of M-CSF. These studies demonstrating in vivo enhancement of anticryptococcal activity of macrophages with M-CSF provide a rationale for in vivo use of M-CSF to enhance resistance to infection with C. neoformans.
Nassar
F
F
Department of Medicine, Santa Clara Valley Medical Center.
Brummer
E
E
Stevens
D A
DA
D000818:Animals; D003453:Cryptococcosis / Q000188:drug therapy* / Q000276:immunology*; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000254:growth & development / Q000276:immunology*; D007279:Injections, Subcutaneous; D007700:Kinetics; D016173:Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D016676:Macrophages, Alveolar / Q000187:drug effects* / Q000382:microbiology*; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000382:microbiology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains
D016173:Macrophage Colony-Stimulating Factor